Atea Pharmaceuticals Inc (AVIR)
3.89
-0.04
(-1.02%)
USD |
NASDAQ |
May 10, 16:00
3.89
0.00 (0.00%)
After-Hours: 20:00
Atea Pharmaceuticals Cash from Operations (TTM): -85.40M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -85.40M |
September 30, 2023 | -85.11M |
June 30, 2023 | -88.76M |
March 31, 2023 | -91.82M |
December 31, 2022 | -120.98M |
September 30, 2022 | -174.86M |
June 30, 2022 | -131.02M |
Date | Value |
---|---|
March 31, 2022 | -129.18M |
December 31, 2021 | -87.00M |
September 30, 2021 | 306.94M |
June 30, 2021 | 274.86M |
March 31, 2021 | 284.40M |
December 31, 2020 | 296.73M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-174.86M
Minimum
Sep 2022
306.94M
Maximum
Sep 2021
12.99M
Average
-87.00M
Median
Dec 2021
Cash from Operations (TTM) Benchmarks
CEL-SCI Corp | -23.07M |
AIM ImmunoTech Inc | -21.27M |
IGC Pharma Inc | -6.19M |
NovaBay Pharmaceuticals Inc | -4.131M |
Protalix BioTherapeutics Inc | -1.318M |